<DOC>
	<DOCNO>NCT00191334</DOCNO>
	<brief_summary>The primary endpoint study assess objective tumor response rate patient advance epithelial ovarian cancer receive combination Gemcitabine dose 1250 mg/m2 ( Day 1 8 ) Cisplatin 75 mg/m2 ( Day 1 ) first-line treatment</brief_summary>
	<brief_title>Gemcitabine Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>ECOG = 02 Operated patient disease stage IIIIV No prior chemotherapy radiation therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>